Targeted Protein Degradation

All categories, Technology Modalities

Single-Atom Edits Redirect a Dual Degrader Scaffold

A bioRxiv preprint reports that small “molecular editing” changes converted LLC0424, a dual NSD2/GSPT1 degrader, into two selective compounds: fluorine substitution produced the NSD2-directed PROTAC 424-ND, while methylene insertion produced the GSPT1 molecular glue…

admin
September 13, 2026

Clinical Trial, Therapeutic Indication

Nurix Enrolls First Patient in Head-to-Head Phase 3 for Bexobrutideg

Nurix Therapeutics enrolled the first participant in DAYBreak CLL-306, a global randomized Phase III trial comparing the BTK degrader bexobrutideg with pirtobrutinib in relapsed or refractory CLL/SLL after progression on a covalent BTK inhibitor….

admin
August 4, 2026

Single-Atom Edits Redirect a Dual Degrader Scaffold

Nurix Enrolls First Patient in Head-to-Head Phase 3 for Bexobrutideg

Saturday Rounds